IMPACT OF CD44 EXPRESSION ON THE EFFECTIVENESS OF TREATMENT OF LOCALLY ADVANCED PRIMARY INOPERABLE BREAST CANCER PATIENTS

Authors:

Abstract:

The study included 157 breast cancer patients aged from 27 to 82 years with ІІIAІІІC stages of the disease, who had no positive response to 6 courses of anthracyclines and/or taxanes-based neo-adjuvant polychemotherapy (AC, FAC, AT). Main group included 74 patients who underwent a course of radiotherapy (RT) under radical program in traditional fractionation mode against the background of daily administration of the cytostatic fluoropyrimidine series drug. Tegafur was used at a dose of 750 mg/m2 daily throughout the radiotherapy course for the purpose of radiomodification. Сomparison group included 83 patients, who underwent radiotherapy alone in traditional fractionation mode. When using RT in conjunction with radiomodifier, we managed to achieve a better response to treatment in our study patients with CD44+ expression, namely to increase the number of partial response by 41.64 % (p=0,02), resectable cases by 17.28 % (p=0.016), to improve the grade of therapeutic pathomorphosis intensity, including through increasing the percentage of reaching pathomorphological complete response by 4.08 % (p=0.03), improving the overall 5-year survival rate by 28.51 % (p=0.01) and progressive-free survival rate by 37.72 % (p<0.001).

Keywords:

breast cancer radiotherapy fluoropyrimidine radioimodifier CD44 tumor response overall survival recurrence-free survival

References:

1. Antomonov MYu. Matematicheskaya obrabotka i analiz mediko-biologicheskikh dannykh. Kyiv: MITs “Medinform”. 2018; 579 р. [in Russian]
2. Grabovoy AN, Tarasova TA, Koshubarova MV. Gistologicheskaya otsenka otveta opukholi na khimioluchevuyu terapiyu. Klinichna onkologiya. 2012; 6(2): 138-43. [inRussian]
3. Ivankova VS, DomIna EA. Problemy rezystentnosti pukhlyn u radiatsiyniy onkolohiyi (klinichni ta radiobiolohichni aspekty): naukove vydannya. Kyiv: Zdorovya. 2012; 192 р. [in Ukrainian]
4. Kim YaS, Kaydina AM, Chang YuH. Molekulyarnye markery rakovykh stvolovykh kletok, verifitsirovannye in vivo. Biomeditsinskaya khimiya. 2016; 62(3): 228–38 [in Russian]
5. Maslyukova EA, Zabroda SI, Koryitova LI. Stvolovye opukholevye kletki – novye gorizonty v prognoze techeniya raka grudnoy zhelezy. Opukholi zhenskoy reproduktivnoy sistemy. 2015; 3: 10-4 [in Russian]
6. Semiglazov VF. Mnogolikaya biologiya raka grudnoy zhelezy: poiski adekvatnogo lecheniya. Zlokachestvennye opukholi. 2016; 3: 5-10 [in Russian]
7. Smirnova IA, Anileeva AA, MatchukON, ZamulaevaIA. Rak grudnoy zhelezy i opukholevye stvolovye kletki. Obzor. Radiatsiya i risk. 2016; 25(4): 31-47 [in Russian]
8. Titov KS, Oganesyan AP, Rotin DL. Opukholevye stvolovye kletki pri rake grudnoy zhelezy. Rol v patogeneze i podkhody k terapii. Zlokachestvennye opukholi. 2016; 2; 22-7. [in Russian]
9. Fedorenko ZP, Mihaylovich YuY, Gulak LO, Rizhov AYu, Goroh EL, SumkIna OV. Rak v Ukrayini, 2018–2019. Zahvoryuvanist, smertnist, pokaznyky diyalnosti onkolohichnoyi sluzhby. Byuleten Natsionalnoho kantser-reestru Ukrayiny. Kyiv, 2020; 21: 102 р. [in Ukrainian]
10. GLOBOCAN 2018 [Internet]. Available from: https://www.iarc.who.int/fr/news-events/latest-global-cancer-data-globocan-database-2020.
11. Kim BM, Hong Y, Lee S, Liu P, Lim JH, Lee YH, et al. Therapeutic Implications for Overcoming Radiation Resistance in Cancer Therapy. Int. J. Mol. Sci. 2015 Nov 10; 16: 26880–913. doi: 10.3390/ijms161125991
12. Liu Y, Nenutil R, Appleyard MV, Murray K, Boylan M, hompson AM, et al. Lack of correlation of stem cell markers in breast cancer stem cells. Br. J. Cancer. 2014 Apr 15; 110: 2063–71. doi: 10.1038/bjc.2014.105
13. Nakshatri H. Radiation resistance in breast cancer: are CD44+/CD24−/proteosomelow/PKH26+ cells to blame? Breast Cancer Res. 2010 Apr 7; 12: 105. doi: 10.1186/bcr2559
14. Ogawa K, Yoshioka Y, Isohashi F, Seo Y, Yoshida K, Yamazaki H. Radiotherapy Targeting Cancer Stem Cells: Current Views and Future Perspectives. Anticancer Res. 2013Mar; 33(3): 747-54.
15. Phillips TM, McBride WH, Pajonk F. Тhe Response of CD24 −/ low/ CD44+Breast Cancer– I nitiating Cells to Radiation. J. Nat. Cancer Inst. 2006Dec 20; 98(24): 1777-85. doi: 10.1093/jnci/djj495

Publication:

«World of Medicine and Biology» Vol. 17 No. 76 (2021) , с. 136-141
УДК 618.19 – 006.6 – 033.2 – 07 – 08

DOI:

https://doi.org/10.26724/2079-8334-2021-2-76-136-141